About the Product

Description


Nimobent 30 Tablet contains Nimodipine 30 mg, a calcium channel blocker primarily used to prevent and treat cerebral vasospasm following subarachnoid hemorrhage. It works by relaxing cerebral blood vessels, improving oxygen and blood flow to the brain, thereby minimizing the risk of ischemic injury.

This medicine is an essential part of neurology and post-stroke care, often prescribed by neurosurgeons and neurologists to support recovery and reduce complications after aneurysmal bleeding.

Belonging to the cardiology-neurology segment, Nimodipine ensures effective neuroprotection, making Nimobent 30 a highly demanded therapeutic option in hospitals, specialized clinics, and critical care units.

For PCD pharma franchise partners, distributors, and third-party manufacturers, Nimobent 30 Tablet provides a profitable B2B opportunity, with steady prescription demand across India. It is suitable for bulk supply, institutional tenders, exports, and third-party manufacturing.

Common side effects may include headache, dizziness, flushing, nausea, or low blood pressure. Rarely, it can cause rapid heartbeat, severe hypotension, or allergic reactions. Seek immediate medical attention if severe symptoms develop.

Nimobent 30 Tablet is indicated for the prevention and management of cerebral vasospasm following subarachnoid hemorrhage. It helps lower the risk of delayed ischemic neurological deficits and supports better recovery after brain hemorrhage.

Take Nimobent 30 Tablet exactly as prescribed and avoid exceeding the recommended dose. Avoid sudden standing or abrupt position changes to prevent dizziness. Inform your doctor if you have heart disease, liver problems, or are taking other blood pressure medications.

Store Nimobent 30 Tablet in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Nimodipine BP 30mg Tablet in the PCD pharma franchise market?

Nimodipine BP 30mg Tablet has demand in the neurology, neurosurgery, critical care, and specialty healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on neurological and hospital care portfolios.

Why should medical distributors include Nimodipine BP 30mg Tablet in their product range?

Medical distributors and agencies can benefit from demand for specialized neurological care under expert medical supervision. Nimodipine BP 30mg is a calcium channel blocker primarily used in neurological and neurosurgical care Commonly prescribed for the prevention and management of cerebral vasospasm following subarachnoid hemorrhage (SAH) as advised by healthcare professionals Helps improve blood flow to the brain by reducing the risk of narrowing of cerebral blood vessels in appropriate patients Plays an important role in post-neurosurgical and neurocritical care management Oral tablet formulation provides convenient administration as part of physician-directed treatment plans Requires careful monitoring of blood pressure and overall clinical status during therapy Frequently utilized in neurology departments, neurosurgery centers, hospitals, and critical care units Widely prescribed by neurologists, neurosurgeons, and critical care specialists This strengthens a comprehensive neurology and specialty hospital care portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Nimodipine BP 30mg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from specialty healthcare market opportunities, hospital-based demand, reliable supply chain support, repeat procurement requirements, and attractive margins in the neurology and critical care segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, wholesalers, and healthcare suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.